Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/26/2904232/0/en/Crossject-elaborates-on-ZEPIZURE-potential-in-light-of-landmark-RAMPART-study-and-its-own-recently-published-bioequivalence-study.html
https://www.globenewswire.com/news-release/2024/06/12/2897279/0/en/Crossject-appoints-Dan-Chiche-MD-as-Chief-Medical-Officer-North-America.html
https://www.globenewswire.com/news-release/2024/06/04/2893354/0/en/Crossject-announces-highly-successful-closing-of-its-8-million-rights-offering.html
https://www.globenewswire.com/news-release/2024/05/30/2890498/0/en/Crossject-announces-publication-of-clinical-data-on-ZEPIZURE-in-Neurology-and-Therapy.html
https://www.globenewswire.com/news-release/2024/05/02/2874473/0/en/Crossject-signs-a-geographic-extension-of-ZEPIZURE-commercialization-agreement-in-Europe.html
https://www.globenewswire.com/news-release/2024/04/25/2869284/0/en/Crossject-reports-audited-financial-results-for-2023.html
https://www.globenewswire.com/news-release/2024/04/02/2855693/0/en/Crossject-advances-in-its-U-S-Strategy-and-reports-Financial-Results-for-2023.html
https://www.globenewswire.com/news-release/2024/04/02/2856338/0/en/Crossject-trading-on-Euronext-to-resume-as-usual-on-Wednesday-April-3.html
https://www.globenewswire.com/news-release/2024/03/08/2842889/0/en/Crossject-gender-equality-score-reaches-96-100-in-2024.html
https://www.globenewswire.com//news-release/2024/02/27/2835681/0/en/Crossject-obtains-a-financing-up-to-12-million-in-two-tranches.html